Serum anti-myomeglin antibodies is a useful tumor marker to detect gastrointestinal cancer

血清抗肌红蛋白抗体是检测胃肠道癌症的有用肿瘤标志物

• 批准号: 17591370
• 负责人: SHIMADA Hideaki
• 金额: $ 2.11万
• 依托单位: Chiba University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2005
• 资助国家: 日本
• 起止时间: 2005 至 2006
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-17591370/
• 关键词: SEREX; Esophageal cancer; Squamous cell carcinoma; tumor marker; prognosis; myomegalin; 胃癌; 大腸癌; 癌抗原; IgG抗体

In order to identify new serum markers of esophageal squamous cell carcinoma (SCC), we performed serological identification of antigens by recombinant cDNA expression cloning (SEREX). E. coli was infected with λZAPII phage cDNA library prepared from mRNA of an esophageal cancer cell line (T.Tn), and IPTG-induced cDNA products were screened for interaction with antibodies in allogeneic sera of patients with esophageal SCC. We identified myomegalin (phosphodiesterase 4D interacting protein/PDE4DIP) as a new SEREX antigen for esophageal SCC. Western blotting analysis revealed that serum anti-myomegalin antibodies (s-myomegalin-Abs) were present in 43 out of 91 (47%) patients but in only one out of 45 (2.2%) healthy controls. Anti-myomegalin Abs were present 38% of stage I patients. The positive rate of s-myomegalin-Abs was the highest among the other conventional tumor markers. Although the presence of s-myomegalin-Abs was not related to any of clinicopathological features of the patients concerned, multivariate analysis indicated that presence of s-myomegalin-Abs was significantly associated with favorable prognosis

为了鉴定食管鳞状细胞癌（SCC）的新血清标志物，我们通过重组cDNA表达克隆（SEREX）进行抗原的血清学鉴定。用食管癌细胞系（T.Tn）的 mRNA 制备的 λZAPII 噬菌体 cDNA 文库感染大肠杆菌，筛选 IPTG 诱导的 cDNA 产物与食管 SCC 患者同种异体血清中抗体的相互作用。我们将肌巨蛋白（磷酸二酯酶 4D 相互作用蛋白/PDE4DIP）确定为食管 SCC 的新 SEREX 抗原。蛋白质印迹分析显示，91 名患者中有 43 名 (47%) 存在血清抗肌巨蛋白抗体 (s-myomegalin-Abs)，但 45 名健康对照中只有 1 名 (2.2%) 存在。 38% 的 I 期患者存在抗肌巨蛋白抗体。 s-myomegalin-Abs在其他常规肿瘤标志物中阳性率最高。尽管 s-myomegalin-Abs 的存在与相关患者的任何临床病理特征无关，但多变量分析表明 s-myomegalin-Abs 的存在与良好的预后显着相关

项目成果

Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin

• DOI: 10.1002/pmic.200500262
• 发表时间: 2006-02-01
• 期刊: PROTEOMICS
• 影响因子: 3.4
• 作者: Nishimori, T;Tomonaga, T;Ochiai, T
• 通讯作者: Ochiai, T

Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma.

• DOI: 10.3892/ijo.28.2.463
• 发表时间: 2006-02
• 期刊: International journal of oncology
• 影响因子: 5.2
• 作者: Mari Kuboshima;H. Shimada;Tianxiang Liu;K. Nakashima;F. Nomura;M. Takiguchi;T. Hiwasa;T. Ochiai

Serological identification of antigens by recombinant cDNA expression cloning (SEREX) using antibodies from patients with esophageal squamous cell carcinoma

使用食管鳞状细胞癌患者的抗体通过重组 cDNA 表达克隆 (SEREX) 进行抗原的血清学鉴定

• 发表时间: 2008
• 作者: Shimada H;Hiwasa T
• 通讯作者: Hiwasa T

An essential role of alternative splicing of c-myc suppressor FUSE-binding protein-interacting repressor in carcinogenesis

• DOI: 10.1158/0008-5472.can-04-4459
• 发表时间: 2006-02-01
• 期刊: CANCER RESEARCH
• 影响因子: 11.2
• 作者: Matsushita, K;Tomonaga, T;Ochiai, T
• 通讯作者: Ochiai, T

Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma.

• DOI: 10.3892/ijo.30.1.97
• 发表时间: 2007
• 期刊: International journal of oncology
• 影响因子: 5.2
• 作者: H. Shimada;Mari Kuboshima;T. Shiratori;Y. Nabeya;A. Takeuchi;H. Takagi;F. Nomura;M. Takiguchi;T. Ochiai;T. Hiwasa